These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36506806)

  • 1. Immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine.
    Yin J; Zhao Y; Huang F; Yang Y; Huang Y; Zhuang Z; Wang Y; Wang Z; Lin X; Zheng Y; Zhou W; Wang S; Xu Z; Ye B; Guo Y; Lei W; Li L; Tian J; Gan J; Wang H; Wang W; Ma P; Liu C; Wei X; Shi X; Wang Z; Wang Y; Liu Y; Yang M; Yuan Y; Song Y; Ma W; Huang Z; Liu Y; Huang Y; Lu H; Liu P; Liang H; Hou Y; Xu X; Liu L; Zhang Y; Wu G; Gao GF; Jin X; Liu C; Yang X; Liu WJ
    Innovation (Camb); 2023 Jan; 4(1):100359. PubMed ID: 36506806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing.
    Tong R; Luo L; Zhao Y; Sun M; Li R; Zhong J; Chen Y; Hu L; Li Z; Shi J; Lyu Y; Hu L; Guo X; Liu Q; Shuang T; Zhang C; Yuan A; Sun L; Zhang Z; Qian K; Chen L; Lin W; Chen AF; Wang F; Pu J
    Emerg Microbes Infect; 2023 Dec; 12(1):e2187245. PubMed ID: 36987861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.
    Szabó E; Modok S; Rónaszéki B; Faragó A; Gémes N; Nagy LI; Hackler L; Farkas K; Neuperger P; Balog JÁ; Balog A; Puskás LG; Szebeni GJ
    Front Med (Lausanne); 2023; 10():1176168. PubMed ID: 37529238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2.
    Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA
    J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults.
    Wang Q; Ning J; Chen Y; Li B; Shi L; He T; Zhang F; Chen X; Zhai A; Wu C
    Front Microbiol; 2022; 13():1008420. PubMed ID: 36406456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunodominant SARS-CoV-2-specific CD4
    Ning J; Wang Q; Chen Y; He T; Zhang F; Chen X; Shi L; Zhai A; Li B; Wu C
    J Med Virol; 2023 Apr; 95(4):e28743. PubMed ID: 37185843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
    Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P
    Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
    Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.
    Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered T-cell receptor β repertoire in adults with SARS CoV-2 inactivated vaccine of BBIBP-CorV.
    Quan Z; Qi A; Ma S; Li Y; Chen H; Yu X; Dong T; Li K; Qiu Y
    Mol Immunol; 2023 Oct; 162():54-63. PubMed ID: 37647774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine.
    Mahmoud S; Ganesan S; Sharif-Askari NS; Cantarutti F; Wilson H; Ogrodzki P; Halwani R; Alkaabi N; Zaher WA
    Curr Med Res Opin; 2022 Dec; 38(12):2069-2075. PubMed ID: 36274640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
    Park S; Gatchalian KK; Oh H
    Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
    Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
    Front Immunol; 2022; 13():967051. PubMed ID: 36159863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity Induced by Inactivated SARS-CoV-2 Vaccine: Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort.
    Chen Y; Hu C; Wang Z; Su J; Wang S; Li B; Liu X; Yuan Z; Li D; Wang H; Zhu B; Shao Y
    Pathogens; 2023 Oct; 12(10):. PubMed ID: 37887770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
    Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
    Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease.
    Wang C; Chen LY; Lu QB; Cui F
    Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sinopharm's BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2.
    Abdelhafiz AS; Ali A; Kamel MM; Ahmed EH; Sayed DM; Bakry RM
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
    Zhang Y; Yang Y; Qiao N; Wang X; Ding L; Zhu X; Liang Y; Han Z; Liu F; Zhang X; Yang X
    Front Med; 2022 Feb; 16(1):93-101. PubMed ID: 35122211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.